Free Trial

Heatwurx (PCSA) Competitors

Heatwurx logo
$0.19 0.00 (-0.51%)
Closing price 07/7/2025 04:00 PM Eastern
Extended Trading
$0.19 +0.00 (+0.10%)
As of 07/7/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PCSA vs. LSB, TLPH, DWTX, AEON, NLSP, CLRB, CHRO, KPRX, TSBX, and BMRA

Should you be buying Heatwurx stock or one of its competitors? The main competitors of Heatwurx include LakeShore Biopharma (LSB), Talphera (TLPH), Dogwood Therapeutics (DWTX), AEON Biopharma (AEON), NLS Pharmaceutics (NLSP), Cellectar Biosciences (CLRB), Chromocell Therapeutics (CHRO), Kiora Pharmaceuticals (KPRX), Turnstone Biologics (TSBX), and Biomerica (BMRA). These companies are all part of the "pharmaceutical products" industry.

Heatwurx vs. Its Competitors

Heatwurx (NASDAQ:PCSA) and LakeShore Biopharma (NASDAQ:LSB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

In the previous week, Heatwurx had 9 more articles in the media than LakeShore Biopharma. MarketBeat recorded 10 mentions for Heatwurx and 1 mentions for LakeShore Biopharma. Heatwurx's average media sentiment score of 0.57 beat LakeShore Biopharma's score of 0.00 indicating that Heatwurx is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Heatwurx
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
LakeShore Biopharma
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Heatwurx currently has a consensus target price of $2.00, suggesting a potential upside of 931.99%. Given Heatwurx's stronger consensus rating and higher possible upside, analysts clearly believe Heatwurx is more favorable than LakeShore Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Heatwurx
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
LakeShore Biopharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Heatwurx has higher earnings, but lower revenue than LakeShore Biopharma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HeatwurxN/AN/A-$11.85M-$3.08-0.06
LakeShore Biopharma$80.82MN/A-$61.09MN/AN/A

Heatwurx has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500. Comparatively, LakeShore Biopharma has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500.

91.9% of Heatwurx shares are owned by institutional investors. Comparatively, 52.6% of LakeShore Biopharma shares are owned by institutional investors. 9.6% of Heatwurx shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

LakeShore Biopharma's return on equity of 0.00% beat Heatwurx's return on equity.

Company Net Margins Return on Equity Return on Assets
HeatwurxN/A -319.56% -232.40%
LakeShore Biopharma N/A N/A N/A

Summary

Heatwurx beats LakeShore Biopharma on 9 of the 12 factors compared between the two stocks.

Get Heatwurx News Delivered to You Automatically

Sign up to receive the latest news and ratings for PCSA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PCSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PCSA vs. The Competition

MetricHeatwurxMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.32M$2.43B$5.52B$9.02B
Dividend YieldN/A1.78%5.24%4.07%
P/E Ratio-0.068.7527.2220.04
Price / SalesN/A473.55380.3292.37
Price / CashN/A21.7726.2128.59
Price / Book0.424.497.945.55
Net Income-$11.85M$31.26M$3.17B$248.49M
7 Day Performance-3.10%1.27%1.81%4.87%
1 Month Performance-35.53%2.46%1.28%6.63%
1 Year Performance-87.96%-0.29%33.57%20.38%

Heatwurx Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PCSA
Heatwurx
3.6234 of 5 stars
$0.19
-0.5%
$2.00
+932.0%
-88.8%$2.32MN/A-0.0620
LSB
LakeShore Biopharma
0.3412 of 5 stars
$0.99
-0.4%
N/AN/A$9.26M$80.82M0.00773Positive News
Gap Up
TLPH
Talphera
1.9295 of 5 stars
$0.46
+2.7%
$5.00
+979.9%
-50.7%$9.25M$650K-1.0319Positive News
DWTX
Dogwood Therapeutics
1.1333 of 5 stars
$4.60
-4.2%
$10.00
+117.4%
N/A$9.17MN/A-0.255Positive News
AEON
AEON Biopharma
3.4751 of 5 stars
$0.79
-5.5%
$360.00
+45,371.8%
-98.9%$8.95MN/A4.405
NLSP
NLS Pharmaceutics
N/A$2.27
-7.0%
N/A+1,101.1%$8.78MN/A0.006Analyst Upgrade
CLRB
Cellectar Biosciences
3.2963 of 5 stars
$4.80
flat
$375.00
+7,712.5%
-93.3%$8.69MN/A-0.2210Gap Down
CHRO
Chromocell Therapeutics
N/A$1.34
+6.3%
N/A-89.1%$8.69MN/A-1.084Gap Up
High Trading Volume
KPRX
Kiora Pharmaceuticals
2.2635 of 5 stars
$2.81
-1.4%
$10.00
+255.9%
-38.8%$8.68MN/A-0.9710Positive News
TSBX
Turnstone Biologics
1.5427 of 5 stars
$0.37
+0.9%
$0.45
+23.3%
-83.7%$8.37MN/A-0.1382
BMRA
Biomerica
0.366 of 5 stars
$3.40
+4.0%
N/A-2.5%$8.32M$5.41M-1.4760

Related Companies and Tools


This page (NASDAQ:PCSA) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners